BR112021021047A2 - Métodos e composições para modulação de emenda e tradução - Google Patents
Métodos e composições para modulação de emenda e traduçãoInfo
- Publication number
- BR112021021047A2 BR112021021047A2 BR112021021047A BR112021021047A BR112021021047A2 BR 112021021047 A2 BR112021021047 A2 BR 112021021047A2 BR 112021021047 A BR112021021047 A BR 112021021047A BR 112021021047 A BR112021021047 A BR 112021021047A BR 112021021047 A2 BR112021021047 A2 BR 112021021047A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- methods
- splicing
- mrna
- expression
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/33—Alteration of splicing
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962838010P | 2019-04-24 | 2019-04-24 | |
| PCT/US2020/029897 WO2020219934A1 (en) | 2019-04-24 | 2020-04-24 | Methods and compositions for modulating splicing and translation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021021047A2 true BR112021021047A2 (pt) | 2022-03-22 |
Family
ID=72941425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021021047A BR112021021047A2 (pt) | 2019-04-24 | 2020-04-24 | Métodos e composições para modulação de emenda e tradução |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220127612A1 (es) |
| EP (1) | EP3958970A4 (es) |
| JP (1) | JP2022529532A (es) |
| KR (1) | KR20220012230A (es) |
| CN (1) | CN114025848A (es) |
| AR (1) | AR119722A1 (es) |
| AU (1) | AU2020262435A1 (es) |
| BR (1) | BR112021021047A2 (es) |
| CA (1) | CA3134329A1 (es) |
| EA (1) | EA202192755A1 (es) |
| IL (1) | IL287398A (es) |
| MX (1) | MX2021012989A (es) |
| SG (1) | SG11202111597UA (es) |
| TW (1) | TW202106877A (es) |
| WO (1) | WO2020219934A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
| US11203591B2 (en) | 2018-10-31 | 2021-12-21 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CA3166000A1 (en) * | 2020-01-28 | 2021-08-05 | Stephen Wilton | Antisense oligomers and methods for treating parkin-related pathologies |
| CN112553328B (zh) * | 2020-12-30 | 2022-06-17 | 浙江大学 | 检测基因表达水平的产品及其在制备重度抑郁症诊断工具中的应用 |
| WO2023239782A2 (en) * | 2022-06-07 | 2023-12-14 | Kicho Inc. | Agents for modulating expression |
| WO2024009306A1 (en) * | 2022-07-07 | 2024-01-11 | Skip Therapeutics Ltd. | Compositions and methods for treating primary ciliary dyskinesia |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054836A1 (en) * | 2000-11-09 | 2005-03-10 | Cold Spring Harbor Laboratory | Chimeric molecules to modulate gene expression |
| JP2010507387A (ja) * | 2006-10-25 | 2010-03-11 | クアーク・ファーマスーティカルス、インコーポレイテッド | 新規のｓｉＲＮＡおよびその使用方法 |
| WO2015035091A1 (en) * | 2013-09-04 | 2015-03-12 | Cold Spring Harbor Laboratory | Reducing nonsense-mediated mrna decay |
| WO2016141236A1 (en) * | 2015-03-03 | 2016-09-09 | Ionis Pharmaceuticals, Inc. | Compositions for modulating mecp2 expression |
| US11969479B2 (en) * | 2017-03-24 | 2024-04-30 | The University Court Of The University Of Edinburgh | MeCP2 expression cassettes |
-
2020
- 2020-04-24 KR KR1020217036111A patent/KR20220012230A/ko unknown
- 2020-04-24 MX MX2021012989A patent/MX2021012989A/es unknown
- 2020-04-24 AR ARP200101174A patent/AR119722A1/es unknown
- 2020-04-24 TW TW109113959A patent/TW202106877A/zh unknown
- 2020-04-24 WO PCT/US2020/029897 patent/WO2020219934A1/en unknown
- 2020-04-24 SG SG11202111597UA patent/SG11202111597UA/en unknown
- 2020-04-24 EP EP20794543.7A patent/EP3958970A4/en active Pending
- 2020-04-24 AU AU2020262435A patent/AU2020262435A1/en active Pending
- 2020-04-24 JP JP2021563215A patent/JP2022529532A/ja active Pending
- 2020-04-24 CN CN202080045541.XA patent/CN114025848A/zh active Pending
- 2020-04-24 EA EA202192755A patent/EA202192755A1/ru unknown
- 2020-04-24 CA CA3134329A patent/CA3134329A1/en active Pending
- 2020-04-24 BR BR112021021047A patent/BR112021021047A2/pt unknown
-
2021
- 2021-10-19 IL IL287398A patent/IL287398A/en unknown
- 2021-11-03 US US17/518,209 patent/US20220127612A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3958970A1 (en) | 2022-03-02 |
| WO2020219934A1 (en) | 2020-10-29 |
| TW202106877A (zh) | 2021-02-16 |
| JP2022529532A (ja) | 2022-06-22 |
| CN114025848A (zh) | 2022-02-08 |
| CA3134329A1 (en) | 2020-10-29 |
| EA202192755A1 (ru) | 2022-03-23 |
| AU2020262435A1 (en) | 2021-12-02 |
| KR20220012230A (ko) | 2022-02-03 |
| MX2021012989A (es) | 2022-01-24 |
| SG11202111597UA (en) | 2021-11-29 |
| AR119722A1 (es) | 2022-01-05 |
| EP3958970A4 (en) | 2023-05-31 |
| IL287398A (en) | 2021-12-01 |
| US20220127612A1 (en) | 2022-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021021047A2 (pt) | Métodos e composições para modulação de emenda e tradução | |
| BR112022002905A2 (pt) | Composições e métodos para modular splicing e expressão de proteína | |
| BR112021005769A2 (pt) | proteínas de ligação a dll3 e métodos de uso | |
| MX2020011786A (es) | Oligomeros antisentido para tratamiento de afecciones y enfermedades. | |
| JOP20210154B1 (ar) | مثبطات kif18a | |
| CL2018001897A1 (es) | Composiciones para modular la expresión de sod-1 (divisional solicitud 201602509) | |
| MX2021007104A (es) | Inhibidores de kif18a. | |
| BR112022004248A2 (pt) | Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, método para inibir a atividade de prmt5 em uma célula, e, método para o tratamento de câncer | |
| EA202192910A1 (ru) | Соединения, направленные на белки, и содержащие их фармацевтические композиции, и их терапевтическое применение | |
| MX2022001302A (es) | Inhibidores de kif18a. | |
| Ackermann et al. | Tendon innervation | |
| MX2022001181A (es) | Inhibidores de kif18a. | |
| BR112021021754A2 (pt) | Cicloalquilas substituídas como moduladoras da via de estresse integrada | |
| BR112017015864A2 (pt) | compostos e métodos para modular a expressão de tmprss6 | |
| BR112019006918A2 (pt) | proteínas actriib variantes e usos das mesmas | |
| BR112015020235A2 (pt) | fragmento biologicamente ativo de proteína csf-1 ou um seu homólogo, ácido nucléico, proteína de fusão, ácido nucléico isolado, vetor, célula hospedeira, método de realização da proteína de fusão do primeiro aspeto da invenção, composição, utilização de uma proteína de fusão, método de tratamento para um indivíduo sofrendo de cancro do fígado e que irá ser submetido a cirurgia, método de tratamento para um indivíduo que irá ser submetido a cirurgia de transplante de fígado, e, kit | |
| BRPI0411020A (pt) | perfil de expressão de gene, métodos de identificar agentes modulares do caminho de wnt, de preparar um perfil de expressão de gene, de triar um agente que realce a remodelagem associada com a carga óssea e reagentes que se ligam às proteìnas que modulam a remodelagem óssea e/ou mineralização óssea, de tratar uma doença ou distúrbio de mineralização óssea, de modular a mineralização óssea em uma célula e a mineralização óssea e/ou remodelagem óssea em um paciente e de determinar se um composto ou uma composição realçam o efeito de carga óssea na atividade/função e/ou mineralização da célula óssea, agente candidato para tratar uma condição de massa óssea baixa e composição | |
| EA201891913A1 (ru) | Улучшенные препараты клеток-предшественников взрослой печени | |
| BR112022010882A2 (pt) | Oligômeros antissenso para tratamento de condições e doenças | |
| BR112021015751A2 (pt) | Vetores de terapia genética para tratamento da doença de danon | |
| BR112021021477A2 (pt) | Composto, composição farmacêutica e método para tratar uma doença mediada por jak em um indivíduo necessitando do mesmo | |
| BR112018011045A2 (pt) | inibidores de oligonucleotídeo anti-sentido (aso) de transportador de monocarboxilato 4 (mct4) para uso como terapêutica no tratamento de câncer | |
| BR112021021676A2 (pt) | Uso de preparação de exossomo de células-tronco mesenquimais para a preparação de composição para o tratamento da doença periodontal | |
| BR112021017710A2 (pt) | Composto, composição farmacêutica, método de tratamento | |
| EA201890623A1 (ru) | Рациональная комбинированная терапия для лечения рака |